At 15 years of follow-up, the cumulative incidence of SMF is equal to 13.4% in CALR-mutated ET, 8.4% in JAK2-mutated ET, and 13.6% in PV cases [9]. The gene discussed is JAK2; the disease is essential thrombocythemia.